A double blind crossover trial of lithium carbonate in asthma.
Lithium carbonate was evaluated in a double-blind, crossover study for prophylactic therapy in five patients with severe perennial asthma. There were no significant differences in symptom scores, salbutamol inhalations, PEFR and pulmonary function tests when the baseline, placebo and lithium periods were compared in all patients.
D000328:Adult; D000420:Albuterol / Q000627:therapeutic use; D001249:Asthma / Q000175:diagnosis / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008094:Lithium / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D016651:Lithium Carbonate; D008297:Male; D008875:Middle Aged; D010366:Peak Expiratory Flow Rate
D016651:Lithium Carbonate; D008094:Lithium; D000420:Albuterol